- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
How Does the Potential for Weight Gain Influence Choice of Therapies?
Zachary T. Bloomgarden, MD, MACE: Weight gain is, of course, an important issue in diabetes. We know that diabetes occurs on a background of obesity in so many individuals. We know that the growth in obesity in the US population, and around the world, has tracked with the increase in the prevalence of diabetes. It’s unfortunate and upsetting that many of the drugs we use in treating diabetes actually are associated with weight gain—in particular, insulin, sulfonylureas, and thiazolidinediones.
So, as a first approximation, one would say we should try to avoid the use of these agents in people with diabetes whenever possible, recognizing that because diabetes is intrinsically a disease with reduced insulin secretory capacity, there are many individuals who simply will require insulin at some point in the natural history of their disease. Also, this new information from the IRIS (Insulin Resistance Intervention after Stroke) trial of pioglitazone recognizes that this may be an insulin sensitizer which reduces the possibility of stroke and myocardial infarction, and that could well outweigh any disadvantage of weight gain.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
